(Post-pandemic Era)-Global Biosimilar Monoclonal Antibody Market Segment Research Report 2022
Table of Contents
Global Biosimilar Monoclonal Antibody Market Segment Research Report 2022
1. Research Scope
2. Market Overview
- 2.1 Product Introduction, Application, Picture
- 2.2 Global Biosimilar Monoclonal Antibody Market by Value
- 2.2.1 Global Biosimilar Monoclonal Antibody Revenue by Type
- 2.2.2 Global Biosimilar Monoclonal Antibody Market by Value (%)
- 2.3 Global Biosimilar Monoclonal Antibody Market by Production
- 2.3.1 Global Biosimilar Monoclonal Antibody Production by Type
- 2.3.2 Global Biosimilar Monoclonal Antibody Market by Production (%)
3. The Major Driver of Biosimilar Monoclonal Antibody Industry
- 3.1 Historical & Forecast Global Biosimilar Monoclonal Antibody Demand
- 3.2 Largest Application for Biosimilar Monoclonal Antibody (2018-2028)
- 3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Biosimilar Monoclonal Antibody Market
- 4.1 Regional Market Size in Terms of Production & Demand (2022)
- 4.2 Regional Market Share in Terms of Revenue (2018-2022)
- 4.3 Concentration Ratio (CR5& CR10) of Biosimilar Monoclonal Antibody Market
- 4.4 Mergers & Acquisitions, Expansion Plans
5. US Biosimilar Monoclonal Antibody Production, Demand (2018-2028)
- 5.1 Current and Estimated Production Breakdown by Type
- 5.2 Current and Estimated Demand Breakdown by Type
- 5.3 Current and Estimated Demand Breakdown by Application
- 5.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
- 5.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Biosimilar Monoclonal Antibody Production, Demand (2018-2028)
- 6.1 Current and Estimated Production Breakdown by Type
- 6.2 Current and Estimated Demand Breakdown by Type
- 6.3 Current and Estimated Demand Breakdown by Application
- 6.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
- 6.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Biosimilar Monoclonal Antibody Production, Demand (2018-2028)
- 7.1 Current and Estimated Production Breakdown by Type
- 7.2 Current and Estimated Demand Breakdown by Type
- 7.3 Current and Estimated Demand Breakdown by Application
- 7.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
- 7.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Biosimilar Monoclonal Antibody Production, Demand (2018-2028)
- 8.1 Current and Estimated Production Breakdown by Type
- 8.2 Current and Estimated Demand Breakdown by Type
- 8.3 Current and Estimated Demand Breakdown by Application
- 8.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
- 8.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Biosimilar Monoclonal Antibody Production, Demand (2018-2028)
- 9.1 Current and Estimated Production Breakdown by Type
- 9.2 Current and Estimated Demand Breakdown by Type
- 9.3 Current and Estimated Demand Breakdown by Application
- 9.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
- 9.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Biosimilar Monoclonal Antibody Production, Demand (2018-2028)
- 10.1 Current and Estimated Production Breakdown by Type
- 10.2 Current and Estimated Demand Breakdown by Type
- 10.3 Current and Estimated Demand Breakdown by Application
- 10.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
- 10.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Biosimilar Monoclonal Antibody Production, Demand (2018-2028)
- 11.1 Current and Estimated Production Breakdown by Type
- 11.2 Current and Estimated Demand Breakdown by Type
- 11.3 Current and Estimated Demand Breakdown by Application
- 11.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
- 11.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. Global Biosimilar Monoclonal Antibody Average Price Trend
- 12.1 Market Price for Each Type of Biosimilar Monoclonal Antibody in US (2018-2022)
- 12.2 Market Price for Each Type of Biosimilar Monoclonal Antibody in Europe (2018-2022)
- 12.3 Market Price for Each Type of Biosimilar Monoclonal Antibody in China (2018-2022)
- 12.4 Market Price for Each Type of Biosimilar Monoclonal Antibody in Japan (2018-2022)
- 12.5 Market Price for Each Type of Biosimilar Monoclonal Antibody in India (2018-2022)
- 12.6 Market Price for Each Type of Biosimilar Monoclonal Antibody in Korea (2018-2022)
- 12.7 Market Price for Each Type of Biosimilar Monoclonal Antibody in Southeast Asia (2018-2022)
13. Industrial Chain (Impact of COVID-19)
- 13.1 Biosimilar Monoclonal Antibody Industrial Chain Analysis
- 13.2 Downstream
- 13.3 Impact of COVID-19
- 13.4 Post-pandemic Era
- 13.5 Technology Trends of Biosimilar Monoclonal Antibody
14. Biosimilar Monoclonal Antibody Competitive Landscape
- 14.1 Biocon
- 14.1.1 Biocon Company Profiles
- 14.1.2 Biocon Product Introduction
- 14.1.3 Biocon Biosimilar Monoclonal Antibody Sales, Revenue (2018-2022)
- 14.1.4 Strategic initiatives
- 14.2 Accord Healthcare
- 14.2.1 Accord Healthcare Company Profiles
- 14.2.2 Accord Healthcare Product Introduction
- 14.2.3 Accord Healthcare Biosimilar Monoclonal Antibody Sales, Revenue (2018-2022)
- 14.2.4 Strategic initiatives
- 14.3 AET Biotech
- 14.3.1 AET Biotech Company Profiles
- 14.3.2 AET Biotech Product Introduction
- 14.3.3 AET Biotech Biosimilar Monoclonal Antibody Sales, Revenue (2018-2022)
- 14.3.4 Strategic initiatives
- 14.4 Amgen
- 14.4.1 Amgen Company Profiles
- 14.4.2 Amgen Product Introduction
- 14.4.3 Amgen Biosimilar Monoclonal Antibody Sales, Revenue (2018-2022)
- 14.4.4 Strategic initiatives
- 14.5 Celltrion
- 14.5.1 Celltrion Company Profiles
- 14.5.2 Celltrion Product Introduction
- 14.5.3 Celltrion Biosimilar Monoclonal Antibody Sales, Revenue (2018-2022)
- 14.5.4 Strategic initiatives
- 14.6 Reddy's Laboratories
- 14.6.1 Reddy's Laboratories Company Profiles
- 14.6.2 Reddy's Laboratories Product Introduction
- 14.6.3 Reddy's Laboratories Biosimilar Monoclonal Antibody Sales, Revenue (2018-2022)
- 14.6.4 Strategic initiatives
- 14.7 Hospira
- 14.7.1 Hospira Company Profiles
- 14.7.2 Hospira Product Introduction
- 14.7.3 Hospira Biosimilar Monoclonal Antibody Sales, Revenue (2018-2022)
- 14.7.4 Strategic initiatives
- 14.8 3SBio
- 14.8.1 3SBio Company Profiles
- 14.8.2 3SBio Product Introduction
- 14.8.3 3SBio Biosimilar Monoclonal Antibody Sales, Revenue (2018-2022)
- 14.8.4 Strategic initiatives
- 14.9 Allergan
- 14.9.1 Allergan Company Profiles
- 14.9.2 Allergan Product Introduction
- 14.9.3 Allergan Biosimilar Monoclonal Antibody Sales, Revenue (2018-2022)
- 14.9.4 Strategic initiatives
- 14.10 Alvartis
- 14.10.1 Alvartis Company Profiles
- 14.10.2 Alvartis Product Introduction
- 14.10.3 Alvartis Biosimilar Monoclonal Antibody Sales, Revenue (2018-2022)
- 14.10.4 Strategic initiatives
15. Conclusion
16. Methodology and Data Source
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
Beijing Yanjing Bizhi Information Consulting Co., Ltd. （XYZResearch）released the 《(Post-pandemic Era)-Global Biosimilar Monoclonal Antibody Market Segment Research Report 2022》, which aims to sort out the development status and trends of the Biosimilar Monoclonal Antibody industry at home and abroad, estimate the overall market scale of the Biosimilar Monoclonal Antibody industry and the market share of major countries, Biosimilar Monoclonal Antibody industry, and study and judge the downstream market demand of Biosimilar Monoclonal Antibody through systematic research, Analyze the competition pattern of Biosimilar Monoclonal Antibody, so as to help solve the pain points of various stakeholders in Biosimilar Monoclonal Antibody industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Biosimilar Monoclonal Antibody Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Biosimilar Monoclonal Antibody Market?
Biocon
Accord Healthcare
AET Biotech
Amgen
Celltrion
Reddy's Laboratories
Hospira
3SBio
Allergan
Alvartis
Major Type of Biosimilar Monoclonal Antibody Covered in XYZResearch report:
Limited Dilution Method
Micromanipulation
Soft Agar Plate Method
Others
Application Segments Covered in XYZResearch Market
Chronic & Autoimmune Diseases
Oncology
Others
For any other requirements, please feel free to contact us and we will provide you customized report.